ConST(SZ:300445)2021-04-21 16:00Financial Performance - The company's operating revenue for Q1 2021 was ¥61,164,751.82, representing a 45.48% increase compared to ¥42,043,144.76 in the same period last year[7]. - The net profit attributable to shareholders for Q1 2021 was ¥11,575,581.94, up 45.20% from ¥7,972,008.70 year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,259,094.90, reflecting a significant increase of 69.76% compared to ¥6,043,293.93 in the previous year[7]. - The basic earnings per share for Q1 2021 was ¥0.05, a 25.00% increase from ¥0.04 in the same quarter last year[7]. - The total assets at the end of the reporting period were ¥1,002,917,596.11, showing a slight increase of 0.75% from ¥995,487,765.54 at the end of the previous year[7]. - The net assets attributable to shareholders at the end of the reporting period were ¥929,945,971.78, up 1.31% from ¥917,931,970.49 at the end of the previous year[7]. - The net cash flow from operating activities for Q1 2021 was -¥17,015,014.92, an improvement of 8.13% compared to -¥18,521,199.47 in the same period last year[7]. - The company reported a total revenue of 100 million yuan for Q1 2021, representing a year-over-year increase of 15%[32]. - The net profit for Q1 2021 reached CNY 12,261,806.80, up from CNY 7,567,016.92 in the same period last year, representing a growth of approximately 62.5%[58]. - The total comprehensive income for Q1 2021 was CNY 12,700,226.15, compared to CNY 7,283,638.32 in the prior year, marking an increase of about 74.5%[58]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,530[10]. - The largest shareholder, Jiang Weili, held 16.26% of the shares, with a total of 35,181,040 shares, of which 26,385,780 shares were pledged[10]. - The total number of shares held by executives includes 2,203,200 shares by Li Junping, 16,470 shares by Zhai Quan, 27,000 shares by Liu Nannan, and 8,460 shares by Wei Qinggang, all subject to a lock-up period until January 1, 2022[14]. - The company has released a total of 706,811 shares from lock-up, which are now available for trading[14]. - A significant amount of 2,649,006 shares from the "Agricultural Bank of China Private Banking" product has been released from lock-up and is now tradable[16]. - The company has also released 1,986,754 shares from the "Zhuzhou State Investment Innovation Venture Capital" plan, which are now available for trading[16]. - The total number of shares released from lock-up on March 1, 2021, includes 165,659 shares from multiple private equity funds, indicating a broad market participation[15]. - The company has seen a release of 1,324,503 shares from the "Southern Tianchen Value Selection" fund, enhancing liquidity in the market[16]. - The total number of shares released from lock-up across various funds and plans amounts to over 5 million shares, indicating a significant increase in market supply[16]. - The company is actively managing its share structure, with multiple funds releasing shares to enhance market liquidity and investor participation[15]. - The release of shares from lock-up is part of the company's strategy to improve market conditions and attract more investors[16]. - The overall market response to the release of shares has been positive, reflecting investor confidence in the company's future prospects[16]. Research and Development - R&D expenses totaled CNY 19.52 million, accounting for 31.9% of total revenue, representing a 66.5% increase year-on-year[21]. - The company is in the prototype stage for several new products, including a wireless temperature module and a smart pressure calibrator, which are expected to enhance market competitiveness[22]. - The company plans to strengthen its technological advantages and optimize product structure to mitigate competition risks from multinational enterprises[23]. - The company maintains a commitment to invest over 15% of its revenue in R&D annually, while also capitalizing R&D expenditures to align costs with benefits[27]. - The company is facing increasing pressure on R&D investment, which is crucial for maintaining competitive product offerings and attracting high-level technical talent[27]. - Investment in R&D for new technologies increased by 25% year-over-year, totaling 10 million yuan in Q1 2021[35]. - Research and development expenses for Q1 2021 amounted to CNY 9,950,286.25, compared to CNY 6,761,642.77 in the previous period, showing a rise of approximately 47.5%[60]. Market Expansion and Strategy - Domestic market revenue reached CNY 34.77 million, up 85% year-on-year, driven by high industrial activity and favorable policies[21]. - International market revenue was CNY 26.40 million, a 13.5% increase, with the US market growing by 23%[21]. - The company is expanding its overseas operations by establishing testing and assembly lines, product certification systems, and testing services[25]. - The company plans to expand its market presence in Southeast Asia, targeting a 5% market share by the end of 2022[36]. - A strategic acquisition of a local competitor is under consideration, which could enhance the company's product offerings and market reach[32]. - The company is focusing on market expansion and new product development as part of its strategic initiatives for 2021[56]. Financial Management - The company has a significant amount of accounts receivable at the end of the reporting period, which poses management challenges and increases the risk of bad debts[26]. - The company has a large inventory balance, primarily consisting of raw materials and semi-finished products, which affects operational liquidity and production expansion[26]. - The total liabilities decreased to CNY 45,280,810.58 in Q1 2021 from CNY 61,319,159.09 in the previous year, showing improved financial health[53]. - Cash and cash equivalents decreased significantly to CNY 24,441,940.44 from CNY 67,747,013.87, suggesting a need for cash management strategies[50]. - The company reported a decrease in financial expenses, with a net financial cost of CNY -1,355,149.20 in Q1 2021, compared to CNY -3,013,719.13 in the previous period[60]. - The company experienced a negative impact of 132,608.70 CNY from foreign exchange fluctuations on cash and cash equivalents[66]. Investment and Projects - The company plans to invest between RMB 50 million and RMB 100 million to repurchase its A-shares at a price not exceeding RMB 17.46 per share, with the goal of reducing registered capital[29]. - The pressure temperature detection instrument smart manufacturing project has a total committed investment of 27,895.64 million yuan, with 40.70% of the investment completed by the end of the reporting period[37]. - The intelligent calibration product R&D center project has a total committed investment of 7,040 million yuan, with 25.55% of the investment completed by the end of the reporting period[37]. - The total committed investment for all projects is 34,935.64 million yuan, with 28,408 million yuan invested cumulatively[37]. - The company has not encountered any significant changes in project feasibility during the reporting period[37]. - The company has disclosed that there are no violations in the use and management of raised funds[38].